ALX-803-335-C100

antibody from Enzo Life Sciences

Targeting: BIRC2 API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Antibody Data

Product number

ALX-803-335-C100

Provider

Enzo Life Sciences

Proper citation

Enzo Life Sciences Cat#ALX-803-335-C100, RRID:AB_2051135

Product name

c-IAP1 monoclonal antibody (1E1-1-10)

Antibody type

Monoclonal

Antigen

Synthetic peptide

Reactivity

Human, Mouse

Host

Rat

Isotype

IgG

Antibody clone number

1E1-1-10

Vial size

100 μg

Storage

-80°C

Handling

Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -80¡C.

References

Submitted references

Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling.

Kocab AJ, Veloso A, Paulsen MT, Ljungman M, Duckett CS
Oncogene 2015 Oct;34(43):5472-81

---

Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination.

de Almagro MC, Goncharov T, Newton K, Vucic D
Cell death & disease 2015 Jun 25;6:e1800

---

An inactivating caspase 11 passenger mutation originating from the 129 murine strain in mice targeted for c-IAP1.

Kenneth NS, Younger JM, Hughes ED, Marcotte D, Barker PA, Saunders TL, Duckett CS
The Biochemical journal 2012 Apr 15;443(2):355-9

---

Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2.

Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, Meier P
Cell death and differentiation 2011 Aug;18(8):1376-86

---

Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding.

Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H, Day CL, Vaux DL, Silke J
The Journal of biological chemistry 2010 Jun 4;285(23):17525-36

---

TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Lluis JM, Nachbur U, Cook WD, Gentle IE, Moujalled D, Moulin M, Wong WW, Khan N, Chau D, Callus BA, Vince JE, Silke J, Vaux DL
PloS one 2010 Jan 8;5(1):e8620

---

Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment.

Geserick P, Hupe M, Moulin M, Wong WW, Feoktistova M, Kellert B, Gollnick H, Silke J, Leverkus M
The Journal of cell biology 2009 Dec 28;187(7):1037-54

---

TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis.

Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, Schmukle AC, Davidson AJ, Callus BA, Wong WW, Gentle IE, Carter H, Lee EF, Walczak H, Day CL, Vaux DL, Silke J
The Journal of biological chemistry 2009 Dec 18;284(51):35906-15

---

TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha.

Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, McKinlay M, Benetatos CA, Condon SM, Chunduru SK, Yeoh G, Brink R, Vaux DL, Silke J
The Journal of cell biology 2008 Jul 14;182(1):171-84

---

IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J
Cell 2007 Nov 16;131(4):682-93

---

A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.

Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, Sage D, Slisz J, Tran M, Straub C, Ramsey T, Iourgenko V, Huang A, Chen Y, Schlegel R, Labow M, Fawell S, Sellers WR, Zawel L
Cancer research 2007 Dec 15;67(24):11493-8

---

Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance.

Silke J, Kratina T, Chu D, Ekert PG, Day CL, Pakusch M, Huang DC, Vaux DL
Proceedings of the National Academy of Sciences of the United States of America 2005 Nov 8;102(45):16182-7

Immunocytochemistry

Supportive validation

Submitted by

Enzo Life Sciences (provider)

Main image

Experimental details

Western blot analysis of c-IAP1 in mouse bone marrow-derived macrophages of the indicated strains lysed in DISC buffer (150mM sodium chloride, 2mM EDTA, 1% Triton X-100, 10% glycerol, 20mM Tris pH 7.5) using MAb to c-IAP1 (1E1-1-10) (Prod. No. ALX-803-335) followed by HRP-anti rat antibody and developed by ECL.Molecular weight marker (kD) is shown at the left. Lanes have been digitally excised from a single blot to aid comparison.

Supportive validation

Submitted by

Enzo Life Sciences (provider)

Main image

Experimental details

Western blot analysis of human c-IAP1 using MAb to c-IAP1 (1E1-1-10)A: MDA-MB-231 cell lysateB: MDA-MB-231 +LBW 1µM/1h cell lysate (LBW causes degradation of c-IAP1; A. Gaither, et al., 2007)(Image courtesy ofÊDr. Pascal Meier, The Institute of Cancer Research, London.)

Supportive validation

Submitted by

Enzo Life Sciences (provider)

Main image

Experimental details

MAb to c-IAP1 (1E1-1-10) is specific for mouse and human c-IAP1. A) Wild type and c-IAP1-/- MEFs were treated +/- TWEAK for 6 hours and whole cell lysates prepared and separated on an SDS-PAGE gel, transferred to a PVDF membrane and probed with MAb to c-IAP1 (1E1-1-10).ÊTWEAK causes a partial loss of c-IAP1. B) 4 human cell lines were treated overnight with an IAP antagonist that induces rapid degradation of c-IAP1. Cells were lysed with DISC lysis buffer and separated on an SDS-PAGE gel, transferred and probed with the MAb to c-IAP1 (1E1-1-10) as in A. XIAP and c-IAP2 blots demonstrate the specificity of the c-IAP1 antibody.